# US 2024/0174988 A1 · Glycoengineering

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0174988 A1
- Document ID: US20240174988A1
- Status: Published application
- Kind: A1
- Application number: 18/142,129
- Filed: 2023-05-02
- Published: 2024-05-30
- Earliest claimed: 2017-12-18
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: Robert M. Anthony; Maya Kitaoka
- Web page: https://patentgrep.com/patent/US20240174988A1

## CPC

- C12N 9/1081: {transferring other glycosyl groups (2.4.99)}
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 9/1051: {Hexosyltransferases (2.4.1)}
- C12Y 204/01038: Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (2.4.1.38)
- C12Y 204/99001: Beta-galactoside alpha-2,6-sialyltransferase (2.4.99.1)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This disclosure relates to glycoengineering, and methods of utilizing glycoengineering for various therapeutic purposes.

## Claims

### Claim 1

A fusion polypeptide comprising:
an antibody heavy chain CH2 region;
an antibody heavy chain CH3 region; and
a catalytic domain of a sialyltransferase, wherein the catalytic domain of the sialyltransferase catalyzes sialylation of a glycoprotein.

### Claim 2 (depends on 1)

The fusion polypeptide of claim 1, wherein the sialyltransferase is beta-galactoside alpha-2,6 sialyltransferase 1.

### Claim 3 (depends on 1)

The fusion polypeptide of claim 1, wherein the sialyltransferase is a human sialyltransferase.

### Claim 4 (depends on 1)

The fusion polypeptide of claim 1, wherein the antibody heavy chain CH2 region comprises a human IgG heavy chain CH2 region.

### Claim 5 (depends on 1)

The fusion polypeptide of claim 1, wherein the antibody heavy chain CH3 region is a human IgG heavy chain CH3 region.

### Claim 6

A fusion polypeptide comprising:
an antibody heavy chain CH2 region;
an antibody heavy chain CH3 region; and
a catalytic domain of galactosyltransferase, wherein the catalytic domain of galactosyltransferase catalyzes galactosylation of a glycoprotein.

### Claim 7 (depends on 6)

The fusion polypeptide of claim 6, wherein the galactosyltransferase is beta-1,4 galactosyltransferase 1.

### Claim 8 (depends on 6)

The fusion polypeptide of claim 6, wherein the galactosyltransferase is a human galactosyltransferase.

### Claim 9 (depends on 6)

The fusion polypeptide of claim 6, wherein the antibody heavy chain CH2 region is a human IgG heavy chain CH2 region.

### Claim 10 (depends on 6)

The fusion polypeptide of claim 6, wherein the antibody heavy chain CH3 region is a human IgG heavy chain CH3 region.

### Claim 11 (depends on 1)

A polynucleotide encoding the fusion polypeptide of claim 1.

### Claim 12 (depends on 1)

A vector comprising a polynucleotide encoding the fusion polypeptide of claim 1.

### Claim 13 (depends on 12)

A cell comprising the vector of claim 12.

### Claim 14

A heteromultimer comprising
a first fusion polypeptide comprising an antibody heavy chain CH2 region, an antibody heavy chain CH3 region, and a catalytic domain of sialyltransferase, wherein the catalytic domain of sialyltransferase catalyzes sialylation of a glycoprotein; and
a second fusion polypeptide comprising an antibody heavy chain CH2 region, an antibody heavy chain CH3 region, and a catalytic domain of galactosyltransferase, wherein the catalytic domain of galactosyltransferase catalyzes galactosylation of a glycoprotein.

### Claim 15 (depends on 14)

The heteromultimer of claim 14, wherein the heteromultimer is a heterodimer, and the first fusion polypeptide associates with the second fusion polypeptide, thereby forming the heterodimer.

### Claim 16 (depends on 14)

The heteromultimer of claim 14, wherein the sialyltransferase is beta-galactoside alpha-2,6 sialyltransferase 1.

### Claim 17 (depends on 14)

The heteromultimer of claim 14, wherein the sialyltransferase is a human sialyltransferase.

### Claim 18 (depends on 14)

The heteromultimer of claim 14, wherein the galactosyltransferase is beta-1,4-galactosyltransferase 1.

### Claim 19 (depends on 14)

The heteromultimer of claim 14, wherein the galactosyltransferase is a human galactosyltransferase.

### Claim 20 (depends on 14)

A method of treating a subject having an IgG-mediated disorder, the method comprising:
administering to the subject an effective amount of a composition comprising the heteromultimer of claim 14.

### Claim at position 21

21-51. (canceled)
